08/05/2026
This is such incredibly welcome news for the Duchenne community 💙
We are so hopeful that this approval will finally mean Jack can access Givinostat through NHS England and benefit from a treatment that could help slow the progression of Duchenne.
Families like ours have waited far too long for opportunities like this. Today feels like a real step forward and gives us renewed hope for the future.
Thank you to everyone who has campaigned tirelessly to make this happen. 💙
On a landmark day for our community, we are delighted to share that the National Institute for Health and Care Excellence (NICE) has recommended givinostat for use on the NHS in England. In final draft guidance issued today, NICE approved the treatment for people with Duchenne muscular dystrophy who are ambulant (able to walk or stand), aged six and older.
After a long and challenging NICE appraisal process that lasted almost two years, and 18 months after the treatment was approved as safe and effective by the Medicines and Healthcare products regulatory agency, this marks a pivotal moment for people with Duchenne.
Today’s news offers real hope for children and young people with Duchenne and their families. It is the culmination of 14 years of work by Duchenne UK, our partners and other organisations, helping to drive advances in research, expand clinical trials and accelerate access to new treatments in the UK.
You can read more about this decision, and what it means, here: duchenneuk.org/givinostat-approved-for-use-in-nhs-england/